Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Antibody drug conjugate (ADC) | 1 |
Therapeutic radiopharmaceuticals | 1 |
Radiolabeled antibody | 1 |
Chemical drugs | 1 |
Target |
Mechanism GABAA receptor modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MUC1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2026 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator University of Melbourne [+10] |
Start Date26 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PEP-CMV vaccine(The University of New South Wales) | Glioblastoma More | Phase 1 |
GT-002 ( GABAA receptor ) | Behavioural disorders More | Phase 1 |
CRLF2-DM1 ( TSLPR ) | Ph-Like Acute Lymphoblastic Leukemia More | Preclinical |
SCH-79797 | Oxygen radical damage More | Preclinical |
SHM-115 | Obesity More | Preclinical |